12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

PRO045 regulatory update

Prosensa said it now has Orphan Drug designation for all 6 of its Duchenne muscular dystrophy (DMD) compounds. FDA and EMA granted Orphan Drug designation to PRO052 and PRO055, while FDA granted Orphan Drug designation to PRO045 and

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >